share_log

S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

S-8:員工福利計劃證券登記
美股SEC公告 ·  06/06 03:02
牛牛AI助理已提取核心訊息
Clene Inc., a biopharmaceutical company, has filed a registration statement on Form S-8 with the Securities and Exchange Commission (SEC) on June 5, 2024. The filing is intended to register an additional 30 million shares of common stock under the Clene Inc. Amended 2020 Stock Plan. This move follows the approval by the company's Board of Directors on April 3, 2024, and by its stockholders on May 29, 2024, to increase the number of shares reserved for issuance from 18.4 million to 48.4 million. The registration statement includes references to prior filings and incorporates by reference the contents of the company's previous registration statements filed on March 29, 2021, and June 16, 2023. The company, headquartered in Salt Lake City, Utah, has designated Robert Etherington, its President and CEO, as the agent for service in this filing.
Clene Inc., a biopharmaceutical company, has filed a registration statement on Form S-8 with the Securities and Exchange Commission (SEC) on June 5, 2024. The filing is intended to register an additional 30 million shares of common stock under the Clene Inc. Amended 2020 Stock Plan. This move follows the approval by the company's Board of Directors on April 3, 2024, and by its stockholders on May 29, 2024, to increase the number of shares reserved for issuance from 18.4 million to 48.4 million. The registration statement includes references to prior filings and incorporates by reference the contents of the company's previous registration statements filed on March 29, 2021, and June 16, 2023. The company, headquartered in Salt Lake City, Utah, has designated Robert Etherington, its President and CEO, as the agent for service in this filing.
生物製藥公司Clene Inc.於2024年6月5日向美國證券交易所(SEC)提交了S-8表格的註冊聲明。該申請旨在在Clene Inc.修訂後的2020年股票計劃下注冊另外3000萬股普通股。此舉是在公司董事會於2024年4月3日和股東於2024年5月29日批准將發行的股票數量從1840萬股增加到4840萬股之後採取的。該註冊聲明包括對之前提交的申請的引用,並引用了公司於2021年3月29日和2023年6月16日提交的之前申請的內容。該公司總部位於猶他州鹽湖城,並將其總裁兼首席執行官羅伯特·埃瑟靈頓指定爲該提交的服務代理人。
生物製藥公司Clene Inc.於2024年6月5日向美國證券交易所(SEC)提交了S-8表格的註冊聲明。該申請旨在在Clene Inc.修訂後的2020年股票計劃下注冊另外3000萬股普通股。此舉是在公司董事會於2024年4月3日和股東於2024年5月29日批准將發行的股票數量從1840萬股增加到4840萬股之後採取的。該註冊聲明包括對之前提交的申請的引用,並引用了公司於2021年3月29日和2023年6月16日提交的之前申請的內容。該公司總部位於猶他州鹽湖城,並將其總裁兼首席執行官羅伯特·埃瑟靈頓指定爲該提交的服務代理人。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。